Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541106 | 1.00 | TSHR (0.47) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL28062034 | 1.00 | TSHR (0.47) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL541372 | 0.99 | TSHR (0.44) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL541861 | 0.95 | TSHR (0.42) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL6852709 | 0.94 | TSHR (0.42) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL5673772 | 0.90 | TSHR (0.44) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL1260811 | 0.90 | TSHR (0.44) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL176508 | 0.89 | THRB (0.38) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL541396 | 0.89 | TSHR (0.46) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL541480 | 0.89 | TSHR (0.46) | TSHRPOLBAPEX1HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189121-A1 | ANTI-THROMBOGENIC MEDICAL DEVICES AND METHODS | COVIDIEN LP | 2024-06-13 | — | — | US | claimed |
| EP-4076916-B1 | WETTABLE SILICONE HYDROGEL CONTACT LENSES | ALCON INC (CH) | 2024-06-12 | — | — | EP | claimed |
| EP-3666299-B1 | ANTI-THROMBOGENIC MEDICAL DEVICES AND METHODS | COVIDIEN LP (US) | 2024-05-15 | — | — | EP | claimed |
| EP-4369081-A2 | METHOD FOR PRODUCING AN OPHTHALMIC PRODUCT | Alcon Inc. (CH) | 2024-05-15 | — | — | EP | claimed |
| EP-4121801-B1 | INSERT MATERIALS WITH HIGH OXYGEN PERMEABILITY AND HIGH REFRACTIVE INDEX | ALCON INC (CH) | 2024-04-17 | — | — | EP | claimed |
| US-11931454-B2 | Wet-packed soft hydrogel ocular inserts | ALCON INC. (CH) | 2024-03-19 | — | — | US | claimed |
| EP-4146461-B1 | METHOD FOR PRODUCING SILICONE HYDROGEL CONTACT LENSES | ALCON INC (CH) | 2024-03-13 | — | — | EP | claimed |
| EP-4118134-B1 | PHOTOCHROMIC POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS | ALCON INC (CH) | 2024-02-28 | — | — | EP | claimed |
| US-11903850-B2 | Anti-thrombogenic medical devices and methods | COVIDIEN LP (US) | 2024-02-20 | — | — | US | claimed |
| US-11867874-B2 | Insert materials with high oxygen permeability and high refractive index | ALCON INC. (CH) | 2024-01-09 | — | — | US | claimed |
| US-10137012-B2 | — | — | 2018-11-27 | — | — | US | claimed |
| EP-3400973-A1 | METHOD OF MANUFACTURING ANTI-THROMBOGENIC MEDICAL DEVICES | Covidien LP (US) | 2018-11-14 | — | — | EP | claimed |
| EP-2875833-B1 | Anti-thrombogenic medical devices and methods | COVIDIEN LP (US) | 2018-08-08 | — | — | EP | claimed |
| US-20170232156-A1 | ANTI-THROMBOGENIC MEDICAL DEVICES AND METHODS | COVIDIEN LP | 2017-08-17 | — | — | US | claimed |
| US-9668890-B2 | Anti-thrombogenic medical devices and methods | COVIDIEN LP (US) | 2017-06-06 | — | — | US | claimed |
| US-20150148882-A1 | ANTI-THROMBOGENIC MEDICAL DEVICES AND METHODS | COVIDIEN LP | 2015-05-28 | — | — | US | claimed |
| WO-2015077081-A1 | ANTI-THROMBOGENIC MEDICAL DEVICES AND METHODS | COVIDIEN LP (US) | 2015-05-28 | — | — | WO | claimed |
| EP-2875833-A1 | Anti-thrombogenic medical devices and methods | Covidien LP (US) | 2015-05-27 | — | — | EP | claimed |
| US-20150140344-A1 | COATED MEDICAL DEVICES | COVIDIEN LP | 2015-05-21 | — | — | US | claimed |
| US-20100094339-A1 | COATING COMPOSITIONS | COVIDIEN LP | 2010-04-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931454-B2 | Wet-packed soft hydrogel ocular inserts | BRI3BP, BRWD1, HRH2 | TSHR 506/4885POLB 3101/4885APEX1 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.